Your essential biotech, medtech, and pharma recap — no noise, just what matters.

Novo's oral Ozempic launch is a calculated brand play. The company is taking an existing product (Rybelsus, oral semaglutide for T2D, available since 2019) and relaunching it in three new dosages under the far more recognizable Ozempic name. Ozempic is one of the most well-known drug brands in the world. Rybelsus was not. The theory: patients and physicians will respond to the Ozempic brand in a way they never did to Rybelsus. The timing, two days before Q1 earnings, is clearly intentional. The pricing is aggressive: $25 for a three-month supply for insured patients is designed to maximize adoption and compete with Lilly's Foundayo ($149/month self-pay lowest dose). Novo is also manufacturing the oral pills entirely in the U.S., which insulates the supply chain from Section 232 tariff exposure. Meanwhile, AbbVie quietly raised its 2026 outlook on the back of strong immunology (Skyrizi, Rinvoq) and neurology growth, continuing a pattern of outperformance as Humira biosimilar erosion stabilizes. AbbVie management described itself as having "ample financial capacity" for M&A, a notable statement given the company has already entered the KRAS space via its Kestrel option deal. And the J.P. Morgan Q1 deal report puts a number on medtech M&A for the first time: $26.6B across 37 deals, driven by large-scale transactions in the device and diagnostics space. 👉 Read Full Analysis

Novo Launches Oral Ozempic Across 70,000 U.S. Pharmacies NVO

What Happened: Novo Nordisk began selling oral Ozempic (semaglutide tablets) in more than 70,000 U.S. pharmacies on Monday May 4. The product is a rebrand of Rybelsus, Novo's existing oral semaglutide for type 2 diabetes, now sold under the far more recognizable Ozempic name in three new dosages (1.5 mg, 4 mg, and 9 mg). Novo has also filed with the FDA for a 25 mg label expansion, with a decision expected by the end of 2026.

The Pricing: Insured patients pay as little as $25 for a three-month prescription. Cash-pay patients using select telehealth providers (WeightWatchers, GoodRx) pay $149/month for the starter dose. Pricing is designed to compete directly with Lilly's Foundayo ($149/month self-pay lowest dose, $25/month insured).

Executive Impact: The rebrand is the most significant commercial move Novo has made in T2D this year. Rybelsus has been available since 2019 but never achieved the commercial traction of injectable Ozempic. By putting the Ozempic name on the pill, Novo is betting that brand recognition will drive adoption in a way that Rybelsus could not. The U.S. manufacturing is strategically important: the pills are made entirely domestically, insulating Novo from Section 232 tariff exposure on the oral franchise.

AbbVie Raises 2026 Outlook on Immunology and Neurology Growth ABBV

AbbVie raised its full-year 2026 outlook after reporting strong Q1 growth in immunology and neurology, according to BioSpace. Skyrizi and Rinvoq continue to grow faster than Humira declines. Neuroscience assets are contributing meaningful revenue. Management highlighted "ample financial capacity" for future M&A, a statement that comes shortly after AbbVie entered the KRAS oncology space with its $1.45B Kestrel option deal. The raised outlook positions AbbVie as one of the few large pharma companies successfully navigating a major patent cliff (Humira) while accelerating growth in new franchises.

J.P. Morgan Q1 2026 Deal Report: Medtech M&A Hits $26.6B

J.P. Morgan published its Q1 2026 biopharma and medtech deal report, providing the most comprehensive data on deal activity across both sectors.

Medtech Highlights:

Biopharma Highlights:

Executive Impact: The medtech M&A figure of $26.6B is notable because it outpaces biopharma M&A in J.P. Morgan's dataset. The device sector is consolidating aggressively, driven by many of the same dynamics as pharma: patent expirations, technology transitions (robotic surgery, AI diagnostics), and competitive positioning ahead of potential Section 232 tariffs on medical devices. The Commerce Department's Section 232 report on medical devices is expected later this month, which could accelerate deal activity as companies seek to build domestic manufacturing capacity.

👉 Read Full Analysis

Rybelsus launched in 2019 and has been a solid performer in the oral T2D space, but never achieved the cultural dominance of injectable Ozempic. Oral Ozempic is the same molecule (semaglutide) in new dosages under a different name. The thesis is that the Ozempic brand, which has massive consumer awareness driven by years of DTC advertising and cultural conversation, will pull patients who would not have asked their doctor about "Rybelsus."

Novo is also layering on pricing incentives. The $25/three-month insured price is lower than most co-pays for branded diabetes drugs. The $149/month cash-pay price matches Foundayo's entry point. And the U.S. manufacturing means Novo can position oral Ozempic as tariff-proof, a talking point that matters for formulary negotiations with PBMs concerned about supply chain risk.

The competitive implication for Lilly: Foundayo now faces two oral Novo products (oral Wegovy for obesity, oral Ozempic for T2D) in addition to injectable competition. Lilly's advantages remain dosing convenience (no fasting) and the ACHIEVE-4 mortality signal. Novo's advantages are brand recognition (Ozempic, Wegovy), a three-month head start in obesity, and now aggressive T2D pricing.

💊 AbbVie's Post-Humira Playbook

AbbVie's raised outlook is significant because it demonstrates that the Humira cliff, which was the industry's most-watched patent event for years, is being successfully navigated. Skyrizi and Rinvoq are growing faster than Humira is declining. The immunology franchise is transitioning, not collapsing.

The "ample financial capacity" language is forward-looking. AbbVie has the Kestrel KRAS option deal ($1.45B), the Humira listing on TrumpRx (86% discount), and now a raised outlook. The company is signaling that it has the balance sheet and confidence to make a larger acquisition in the second half of 2026.

📊 Medtech M&A: The Underreported Story

The biopharma M&A wave has dominated headlines, but medtech M&A is running at a similar pace. J.P. Morgan's $26.6B across 37 deals in Q1 puts medtech on pace for over $100B in annual deal value.

Key drivers: the Section 232 investigation on medical devices (launched September 2025, report expected late May) is creating urgency for companies to build domestic manufacturing capacity. Robotic surgery (Intuitive, Medtronic Hugo) is driving consolidation in surgical tools and instrumentation. AI diagnostics companies are being acquired by large device makers seeking software capabilities. And the medtech IPO market, while more selective than biopharma (one IPO at $600M vs. six biopharma IPOs), is showing signs of reopening.

For BD teams and investors: medtech M&A deserves as much attention as biopharma in 2026. The drivers are similar (technology transitions, regulatory pressure, scale advantages) and the deal volume is comparable.

🎯 Catalyst Calendar: May 2026 Forward

👉 Visit The Pro Hub

Is your company listed in the BioMed Nexus directory? 2,104 companies across 14 categories. Claim or upgrade your listing →

Sponsorship slots for 2026 are limited. See packages and pricing →